Bricaire F
Presse Med. 1996;25(8):327-9.
Since Ramon developed the anti-diphtheria anatoxin in 1924 widespread vaccination has almost eliminated diphtheria, but since the acquired immunity is anatoxic and not anti-bacterial, carriage of the causal agent Corynebacterium diphteriae remains possible. In 1990, 1214 declared cases of diphtheria inaugurated an epidemic which spread through Russia, Ukraine and neighboring countries and even reached a few subjects in Europe and North America. Mortality in Russia was 10.15 per 100000 cases in 1993. Higher rates were observed in children. The question is raised as to the level of protection in Western countries despite generalized vaccination programs. In France, a recent survey showed that only 49.3% of the 1004 subjects evaluated had complete protection and 20.4% had no protection at all. While 95% of young adults in the 15 to 24 age range were protected, the rate of protection was below one-third in subjects over 65. These results emphasize the importance of anti-diphtheria vaccination programs and continued surveillance in adult populations. Current French legislation requires vaccination before the age of 18 months but without any requirement for re-vaccination in adults. The current situation clearly demonstrates that the risk of a diphtheria epidemic still exists, even in our Western countries. To completely protect the population, the present vaccination policy should include re-vaccinations of the adult population every 10 years, as for tetanus. Use of a preparation containing a reduced dose of vaccine, given with the tetanus and polio booster shots, is to be recommended. Re-vaccination with DT or the reduced dose dT would also be indicated after injury instead of tetanus alone. Surveillance and typing of C. diphteriae strains isolated from clinical cases should also be maintained.
自1924年拉蒙研制出抗白喉抗毒素以来,广泛接种疫苗几乎已消除了白喉,但由于获得的免疫力是抗毒素性的而非抗细菌性的,致病因子白喉棒状杆菌的携带仍有可能。1990年,1214例申报的白喉病例引发了一场疫情,疫情蔓延至俄罗斯、乌克兰及周边国家,甚至波及了欧洲和北美的一些人。1993年俄罗斯的死亡率为每10万例10.15人。儿童中的死亡率更高。尽管有普遍的疫苗接种计划,但西方国家的保护水平仍受到质疑。在法国,最近一项调查显示,在接受评估的1004名受试者中,只有49.3%有完全的保护,20.4%根本没有保护。虽然15至24岁年龄组的年轻成年人中有95%受到了保护,但65岁以上受试者的保护率低于三分之一。这些结果强调了抗白喉疫苗接种计划以及对成年人群持续监测的重要性。法国现行法律要求在18个月龄前接种疫苗,但对成年人再次接种没有任何要求。目前的情况清楚地表明,即使在我们西方国家,白喉疫情的风险仍然存在。为了全面保护人群,目前的疫苗接种政策应包括每10年对成年人群进行一次再次接种,如同破伤风疫苗那样。建议使用含有减量疫苗的制剂,与破伤风和脊髓灰质炎加强针一起接种。受伤后也应接种白喉破伤风联合疫苗(DT)或减量的白喉破伤风疫苗(dT),而不仅仅是破伤风疫苗。还应持续监测从临床病例中分离出的白喉棒状杆菌菌株并进行分型。